Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


TiGenix’s New European Production Facility Obtains EMA Approval for Commercial Production of ChondroCelect 

 

September 25, 2012 - (TiGenix) - "TiGenix announced today that after the successful cGMP inspection by the Dutch authorities earlier this year, it has now obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company’s commercial cell therapy product for cartilage repair in the knee, in its new state-of-the-art manufacturing facility in Sittard Geleen (NL)."  Read Full Article

 

Posted on 8-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: